AstraZeneca's Tozorakimab Shows Positive Results in Two Late-Stage COPD Trials

AstraZeneca's experimental drug tozorakimab has produced positive results in two late-stage clinical trials for chronic obstructive pulmonary disease (COPD), according to a report by CNBC.

The full data from the trials reinforces expectations that the drug could represent a breakthrough treatment for COPD, the report said.

CNBC reported that the results support AstraZeneca's forecast that tozorakimab could reach peak annual sales of more than $5 billion, positioning it as a potential blockbuster medicine for the company.

COPD is a progressive lung disease that makes breathing difficult and affects millions of people worldwide. Treatments that can significantly improve outcomes for patients are considered commercially significant for pharmaceutical companies given the scale of the condition.

Further details on the specific trial design, patient outcomes, and timeline for regulatory submission were not immediately available in the source report.